Articles les plus consultés

mercredi 4 avril 2018

Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 Meeting | Business Wire

Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 Meeting | Business Wire: Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that dat

U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations | Business Wire

U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations | Business Wire: Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application and granted priority review f

Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York

Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York

NICE rejette Dupixent pour une dermatite atopique pour des raisons de coûts, répond Sanofi | Pharmafile

NICE rejette Dupixent pour une dermatite atopique pour des raisons de coûts, répond Sanofi | Pharmafile

Global Autism Project Partners With Leading Technology and Behavioral Health Experts Rethink

Global Autism Project Partners With Leading Technology and Behavioral Health Experts Rethink

Tilray® Launches High Park Company™ to Produce and Distribute Adult-Use Cannabis in Canada | Business Wire

Tilray® Launches High Park Company™ to Produce and Distribute Adult-Use Cannabis in Canada | Business Wire: Tilray is launching wholly-owned subsidiary High Park to produce and distribute a broad-based portfolio of cannabis brands and products.

Terns Pharmaceuticals获得礼来公司(Eli Lilly and Company)三项NASH资产的全球独家开发和商业化权益 | Business Wire

Terns Pharmaceuticals获得礼来公司(Eli Lilly and Company)三项NASH资产的全球独家开发和商业化权益 | Business Wire: (美国商业资讯) -- Terns Pharmaceuticals Inc.是一家全球性生物制药公司,致力于治疗肝病和癌症的口服小分子创新药物的研发,该公司今天宣布已与礼来公司签署全球性授权协议,获得三个有望用于治疗非酒精性脂肪性肝炎(NASH)的小分子候选药物的全球独家开发和商业化权益。协议包括临